Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial

Table 2

Changes of renal function before and after the procedure between the two groups.

Group	Cystatin C (mg/L)	SCr (mol/L)	eGFR (mL/min)
BNP group ()
Baseline	1.14 ± 0.22	117.2 ± 13.1	52.3 ± 11.2
After procedure
24 h	1.44 ± 0.31^#	133.2 ± 14.1^#	46.3 ± 15.4^#
48 h	1.56 ± 0.29^#	140.1 ± 13.9^#	43.6 ± 17.1^#
1 week	1.20 ± 0.24	123.8 ± 14.4	50.4 ± 14.9
1 month	1.16 ± 0.20	120.7 ± 15.1	50.9 ± 18.2
Control group ()
Baseline	1.17 ± 0.36	120.5 ± 14.7	50.9 ± 9.3
After procedure
24 h	1.51 ± 0.44^#	137.4 ± 14.1^#	46.8 ± 12.6
48 h	1.75 ± 0.94	151.2 ± 15.9	40.2 ± 18.7
1 week	1.88 ± 0.82	159.7 ± 13.8	37.9 ± 15.9
1 month	1.19 ± 0.26	129.6 ± 14.6	48.2 ± 15.7

SCr: serum creatinine; eGFR: estimated glomerular filtration rate.
⁢ versus the BNP group (data were analyzed using the independent samples -test). versus baseline within the same group (data were analyzed using repeated measure ANOVA and the Bonferroni post hoc test).